Clinical associations of Trousseau's syndrome associated with cerebral infarction and ovarian cancer

Objective Since there have been few large series studies to date, we investigated the relationship between Trousseau's syndrome associated with cerebral infarction and its clinical associations with ovarian cancer. Methods In this study, we investigated the association between cerebral infarction onset and ovarian cancer. Eight-hundred twenty-seven consecutive ovarian cancer patients from 4 affiliated academic institutions were included in the study over a 12 years period. All patients were histopathologically diagnosed as epithelial ovarian cancer and were analyzed retrospectively. Results The 27 patients (3.2%) presented with cerebral infarction during the study period, 14 patients onset prior to treatment (1.7%), and 13 patients onset after start of initial treatment (1.5%). Univariate analysis and multivariate analysis was performed for onset of Trousseau's syndrome and various clinical and pathological parameters. There was no statistical significance between the occurrence of Trousseau's syndrome with age or International Federation of Gynecology and Obstetrics (FIGO) stage; however, univariate analysis and multivariate analysis demonstrated a statistically significant association between clear cell carcinoma (CCC) and non-CCC histology. Conclusion Thus, our results demonstrate that Trousseau's syndrome with cerebral infarction occurred with greater incidence among CCC cases compared to non-CCC cases.

[1]  T. Hachisuga,et al.  Clinical statistics of gynecologic cancers in Japan , 2017, Journal of gynecologic oncology.

[2]  S. Kyo,et al.  Case series of cerebral infarction with Trousseau's syndrome associated with malignant gynecological tumors. , 2016, Molecular and clinical oncology.

[3]  M. Sakayori,et al.  Trousseau's syndrome: cancer-associated thrombosis. , 2016, Japanese journal of clinical oncology.

[4]  B. Karlan,et al.  Venous thromboembolism during primary treatment of ovarian clear cell carcinoma is associated with decreased survival. , 2013, Gynecologic oncology.

[5]  N. Horowitz,et al.  When 'never-events' occur despite adherence to clinical guidelines: the case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes. , 2010, Gynecologic oncology.

[6]  H. Chew,et al.  Venous thromboembolism in ovarian cancer. , 2007, Gynecologic oncology.

[7]  C. Klersy,et al.  Ovarian cancer and venous thromboembolic risk. , 2005, Gynecologic oncology.

[8]  A A Rimm,et al.  Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. , 1999, Medicine.

[9]  J. Olsen,et al.  The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. , 1998, The New England journal of medicine.

[10]  M. Piver,et al.  Lack of improved survival plus increase in thromboembolic complications in patients with clear cell carcinoma of the ovary treated with platinum versus nonplatinum‐based chemotherapy , 1996, Cancer.

[11]  J. Cain,et al.  Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease. , 1996, Gynecologic oncology.

[12]  K. Crickard,et al.  Clear cell ovarian adenocarcinoma , 1984, Journal of surgical oncology.

[13]  J. Levin,et al.  Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. , 1977, Medicine.